DelSiTech and Tolmar announce global license and development agreement

Betsy Goodfellow | February 13, 2024 | News story | Medical Communications DelSiTech, Pharmacy, Tolmar, collaboration 

DelSiTech and Tolmar International have announced that they have entered into a global license and development agreement, following a previous investment from Tolmar in January 2024.

Under the terms of this agreement, Tolmar will gain the global license to utilise DelSiTech’s proprietary, silica-based drug delivery technology platform for the development and commercialisation of two currently undisclosed injectable drug compounds. Both companies are expected to collaborated for further development opportunities using controlled release drug products based on Silica Matrix, for various therapeutic areas including urology, reproductive health and paediatric endocrinology.

DelSiTech will be eligible to receive an upfront payment, as well as development and commercial milestone payments and royalties on net sales of licensed products, although no amounts have as yet been disclosed.

Lasse Leino, chief executive officer at DelSiTech, commented: “We are thrilled to expand our partnership with Tolmar, which further validates the potential of our proprietary, silica-based, drug delivery technology platform. By joining forces and combining our expertise in advanced drug delivery technologies, we have the ability and potential to develop novel products for the benefit of patients in need of improved therapies. The licensing agreement is a natural next step, following investment from Tolmar at the beginning of this year.”

Betsy Goodfellow

Related Content

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

BenevolentAI has announced that AstraZeneca has added a novel heart failure target to its discovery …

Fulcrum Therapeutics and Sanofi enter collaboration for facioscapulohumeral muscular dystrophy treatment

Fulcrum Therapeutics has announced that it has entered into a collaboration and license agreement with …

lungs

Gossamer Bio and Chiesi Group enter into international collaboration to commercialise Seralutinib

US-based clinical stage biopharma company Gossamer Bio and Italian research-focused biopharma group Chiesi Farmaceutici have …

Latest content